Warning! The directory is not yet complete and will be amended until the beginning of the term.
322013 UE Case Studies and Pharmaceutical Care - M9 (2024S)
(5 Kurse)
Continuous assessment of course work
Labels
Anmeldung in 2 Schritten:
1. U:Space 322013 ( https://uspace.univie.ac.at/ )
UND
2. Anmeldesystem Pharmazie ( https://spl-pharmazie.univie.ac.at/anmeldesystemPHARMAZIE/ )Vorlesungszeiten: nähere Informationen siehe Homepage
https://pharmtox.univie.ac.at/studenten/praktika/ue-fallstudien-pharmazeutische-betreuung-m9/
1. U:Space 322013 ( https://uspace.univie.ac.at/ )
UND
2. Anmeldesystem Pharmazie ( https://spl-pharmazie.univie.ac.at/anmeldesystemPHARMAZIE/ )Vorlesungszeiten: nähere Informationen siehe Homepage
https://pharmtox.univie.ac.at/studenten/praktika/ue-fallstudien-pharmazeutische-betreuung-m9/
Registration/Deregistration
Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).
- Registration is open from Th 25.01.2024 12:00 to Th 15.02.2024 12:00
- Deregistration possible until Th 15.02.2024 12:00
Details
Language: German
Lecturers
Classes (iCal) - next class is marked with N
- Tuesday 05.03. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
- Thursday 14.03. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
- Tuesday 19.03. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
- Thursday 21.03. 16:45 - 20:00 UZA2 Hörsaal 8 (Raum 2Z206) 2.OG
- Thursday 21.03. 20:15 - 21:00 UZA2 Hörsaal 8 (Raum 2Z206) 2.OG
- Tuesday 09.04. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
- Tuesday 16.04. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
-
Tuesday
23.04.
16:45 - 20:00
UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
UZA2 Hörsaal 8 (Raum 2Z206) 2.OG -
Tuesday
30.04.
16:45 - 20:00
UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
UZA2 Hörsaal 8 (Raum 2Z206) 2.OG -
Tuesday
07.05.
16:45 - 20:00
UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
UZA2 Hörsaal 8 (Raum 2Z206) 2.OG - Tuesday 14.05. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
- Thursday 16.05. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
- Tuesday 21.05. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
- Thursday 23.05. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
-
Tuesday
28.05.
16:45 - 20:00
UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
UZA2 Hörsaal 8 (Raum 2Z206) 2.OG - Tuesday 04.06. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
- Tuesday 11.06. 16:45 - 20:00 UZA2 Hörsaal 5 (Raum 2Z202) 2.OG
- Tuesday 18.06. 15:00 - 20:00 UZA2 Hörsaal 7 (Raum 2Z210) 2.OG
- Tuesday 25.06. 15:00 - 20:00 UZA2 Hörsaal 7 (Raum 2Z210) 2.OG
Information
Aims, contents and method of the course
Assessment and permitted materials
-) Module 1-3: Application of knowledge to a specific case study appropriate to the topic
-) At the end of each module, the associated basic knowledge is held in the form of an examination-) After module 3, complex case studies are given in 2 units (held on 2 different dates)
-) Written examPermitted resources: guidelines, specialist information and interaction software
-) At the end of each module, the associated basic knowledge is held in the form of an examination-) After module 3, complex case studies are given in 2 units (held on 2 different dates)
-) Written examPermitted resources: guidelines, specialist information and interaction software
Minimum requirements and assessment criteria
▪ Attendance (≥ 70%)
▪ Module 1-3: Collaboration and knowledge testing or presentation (10 points per module)
▪ Written thesis (70 points)
However, the written thesis must be completed positively!
The points achieved for the respective partial achievements are added together, whereby at least half of the points to be achieved must be achieved for each partial achievement. The total number of points determined together with the final examination (at least 50% must be achieved) results in the overall grade.
Total possible number of points: 100 points
At least 50% (= at least 50 points) is required for a positive assessment.
Clef: 0-49.5 p. (5), 50-62 p. (4), 63-75 p. (3), 76-88 p. (2), 89-100 p. (1)
▪ Module 1-3: Collaboration and knowledge testing or presentation (10 points per module)
▪ Written thesis (70 points)
However, the written thesis must be completed positively!
The points achieved for the respective partial achievements are added together, whereby at least half of the points to be achieved must be achieved for each partial achievement. The total number of points determined together with the final examination (at least 50% must be achieved) results in the overall grade.
Total possible number of points: 100 points
At least 50% (= at least 50 points) is required for a positive assessment.
Clef: 0-49.5 p. (5), 50-62 p. (4), 63-75 p. (3), 76-88 p. (2), 89-100 p. (1)
Examination topics
The material taught in the course.
Reading list
Auf spezielle Literatur wird während der einzelnen Einheiten verwiesen.
Association in the course directory
MA13
Last modified: Th 22.02.2024 17:27
-) Principles of clinical-pharmaceutical care
-) Causes, symptoms, diagnosis and guideline-compliant therapy of various diseases, taking laboratory parameters into account
-) Identification of drug-related problems caused by potentially inadequate medication, including self-medication (drug interactions, side effects, application errors and adherence)
-) Dosing of drugs taking into account special patient needsThis exercise is offered in 4 modules with the following content:
-) Module 1: Introduction to medication analysis, laboratory diagnostics and hypertension
-) Module 2: heart failure, myocardial infarction and respiratory diseases
-) Module 3: Atrial fibrillation and stroke prophylaxis; Thrombosis and embolism prophylaxis; Dyslipidemias and lipid lowering agents, pharmaceutical management of diabetes mellitusThe individual modules (1-3) are each composed of introductory lectures and workshops. During the workshops, case studies are worked on either in plenary sessions or in small groups. The exercise concludes with a thesis in the nature of an examination, where the knowledge acquired from all modules is applied. Guidelines and specialist information are available here to assist you.